| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S15231 R63057 |
Dreier (Carbamazepine) (Epilepsy) (Controls exposed to LTG), 2023 | Attention-deficit/hyperactivity disorder (ADHD) - Corresponding ICD-10 F-chapter - Up to 22 years of age | during pregnancy (anytime or not specified) | population based cohort propective | exposed to other treatment, sick excluded | Adjustment: No |
1.89 [1.41;2.53] C excluded (control group) |
89/2,665 95/5,288 | 184 | 2,665 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15235 R63058 |
Dreier (Carbamazepine) (Epilepsy) (Controls unexposed, sick), 2023 | Attention-deficit/hyperactivity disorder (ADHD) - Corresponding ICD-10 F-chapter - Up to 22 years of age | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, sick | Adjustment: Yes | 1.05 [0.81;1.37] | 89/2,665 528/22,203 | 617 | 2,665 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9749 R46371 |
Wiggs (Carbamazepine), 2020 | Attention-deficit/hyperactivity disorder (after 2 years of age) | at least 1st trimester | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 1.18 [0.91;1.52] | -/- -/11,298 | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9723 R46370 |
Huber-Mollema (Carbamazepine), 2019 | Diagnosis of ADHD | throughout pregnancy | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.95 [0.18;5.12] C | 2/37 5/88 | 7 | 37 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9734 R46372 |
Richards (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2019 | The Strengths and Difficulties Questionnaire - parent-completed (SDQP) Hyperactivity ≥7 (at 4 years old) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: Yes |
0.86 [0.45;1.67] excluded (control group) |
17/201 13/149 | 30 | 201 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9735 R46373 |
Richards (Carbamazepine) (Controls unexposed, NOS) (Indications NOS), 2019 | The Strengths and Difficulties Questionnaire - parent-completed (SDQP) Hyperactivity ≥7 (at 4 years old) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes | 1.83 [1.11;3.02] | 17/201 11,841/286,966 | 11,858 | 201 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9696 R46364 |
Bromley (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2013 | Attention deficit hyperactivity disorder (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.82 [0.07;46.28] C excluded (control group) |
1/50 0/30 | 1 | 50 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9699 R46365 |
Bromley (Carbamazepine) (Controls unexposed, disease free), 2013 | Attention deficit hyperactivity disorder (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No |
13.21 [0.53;329.15] C excluded (control group) |
1/50 0/214 | 1 | 50 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9702 R46366 |
Bromley (Carbamazepine) (Controls unexposed, sick), 2013 | Attention deficit hyperactivity disorder (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 1.58 [0.06;40.13] C | 1/50 0/26 | 1 | 50 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9711 R46369 |
Cohen (Carbamazepine), 2013 | Children with either ADHD inattentive OR combined types > 1 SD (from the Attention Problems and Hyperactivity scales of the BASC) (Both Parent and Teacher) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.96 [0.22;4.25] C | 4/32 4/31 | 8 | 32 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9743 R46374 |
Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) b, 2013 | ADHD symptoms ≥ 2SD (at 36 months) (Specific checklist) (Parent-reported) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.94 [0.15;6.00] C excluded (control group) |
2/31 3/44 | 5 | 31 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9745 R46375 |
Veiby (Carbamazepine) (Controls unexposed, disease free) b, 2013 | ADHD symptoms ≥ 2SD (at 36 months) (Specific checklist) (Parent-reported) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No |
2.00 [0.50;8.60] excluded (control group) |
2/31 1,743/43,571 | 1,745 | 31 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9746 R46376 |
Veiby (Carbamazepine) (Controls unexposed, sick) b, 2013 | ADHD symptoms ≥ 2SD (at 36 months) (Specific checklist) (Parent-reported) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 2.59 [0.45;14.78] C | 2/31 4/154 | 6 | 31 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9747 R46377 |
Viinikainen (Carbamazepine) b, 2006 | Conners' Teacher Rating Scale Global Index scores >1 SD | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 0.15 [0.01;3.50] C | 0/12 2/11 | 2 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 8 studies | 1.18 [1.00;1.40] | 12,499 | 3,028 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Carbamazepine) (Epilepsy) (Controls unexposed, sick; 2: Carbamazepine; 3: Carbamazepine; 4: Carbamazepine) (Controls unexposed, NOS) (Indications NOS; 5: Carbamazepine) (Controls unexposed, sick; 6: Carbamazepine; 7: Carbamazepine) (Controls unexposed, sick) ; 8: Carbamazepine) ;
Asymetry test p-value = 0.9547 (by Egger's regression)
slope=0.1592 (0.1288); intercept=0.0313 (0.5281); t=0.0592; p=0.9547
excluded 9696, 9699, 9743, 9745, 9734, 15231